MARKET

GHRS

GHRS

Gh Research Plc
NASDAQ
23.84
-0.61
-2.49%
After Hours: 23.84 0 0.00% 19:30 09/25 EDT
OPEN
24.48
PREV CLOSE
24.45
HIGH
24.55
LOW
23.49
VOLUME
179.99K
TURNOVER
--
52 WEEK HIGH
31.44
52 WEEK LOW
12.04
MARKET CAP
1.64B
P/E (TTM)
-24.1467
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GHRS last week (0914-0918)?
Weekly Report · 5d ago
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities
Seeking Alpha · 6d ago
Weekly Report: what happened at GHRS last week (0907-0911)?
Weekly Report · 09/14 09:21
GH Research Plans Investor Meetings at Morgan Stanley Global Healthcare Conference
TipRanks · 09/11 11:28
FDA names acting heads of drug and vaccine units to permanent roles
Seeking Alpha · 09/09 00:25
Weekly Report: what happened at GHRS last week (0831-0904)?
Weekly Report · 09/07 09:19
Analysts Offer Insights on Healthcare Companies: GH Research (GHRS), Evaxion Biotech (EVAX) and Ibio (IBIO)
TipRanks · 08/31 14:00
Weekly Report: what happened at GHRS last week (0824-0828)?
Weekly Report · 08/31 09:21
More
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.

Webull offers GH Research PLC stock information, including NASDAQ: GHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GHRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GHRS stock methods without spending real money on the virtual paper trading platform.